
EquitySector - HealthcareVery High Risk
Regular
NAV (24-Oct-25)
Returns (Since Inception)
Fund Size
₹1,896 Cr
Expense Ratio
2.08%
ISIN
INF179KC1HL7
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.65%
+3.55% (Cat Avg.)
Since Inception
+30.65%
— (Cat Avg.)
| Equity | ₹1,876.57 Cr | 98.97% |
| Others | ₹19.54 Cr | 1.03% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹198.43 Cr | 10.47% |
| Divi's Laboratories Ltd | Equity | ₹147.07 Cr | 7.76% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹131.38 Cr | 6.93% |
| Lupin Ltd | Equity | ₹129.64 Cr | 6.84% |
| Alkem Laboratories Ltd | Equity | ₹112.58 Cr | 5.94% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹88.28 Cr | 4.66% |
| Ipca Laboratories Ltd | Equity | ₹85.33 Cr | 4.50% |
| Cipla Ltd | Equity | ₹81.83 Cr | 4.32% |
| Torrent Pharmaceuticals Ltd | Equity | ₹72.28 Cr | 3.81% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹68.94 Cr | 3.64% |
| Laurus Labs Ltd | Equity | ₹67.88 Cr | 3.58% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹67.4 Cr | 3.55% |
| Anthem Biosciences Ltd | Equity | ₹61.72 Cr | 3.26% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹60.53 Cr | 3.19% |
| Metropolis Healthcare Ltd | Equity | ₹50.04 Cr | 2.64% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹46.41 Cr | 2.45% |
| Acutaas Chemicals Ltd | Equity | ₹43.72 Cr | 2.31% |
| Gland Pharma Ltd | Equity | ₹40.24 Cr | 2.12% |
| Wockhardt Ltd | Equity | ₹39.16 Cr | 2.07% |
| Cohance Lifesciences Ltd | Equity | ₹37.67 Cr | 1.99% |
| Dr. Lal PathLabs Ltd | Equity | ₹36.79 Cr | 1.94% |
| Fortis Healthcare Ltd | Equity | ₹35.8 Cr | 1.89% |
| Jubilant Pharmova Ltd | Equity | ₹34.28 Cr | 1.81% |
| Piramal Pharma Ltd | Equity | ₹33.88 Cr | 1.79% |
| Sai Life Sciences Ltd | Equity | ₹31.68 Cr | 1.67% |
| Bajaj Healthcare Ltd | Equity | ₹25.48 Cr | 1.34% |
| Pfizer Ltd | Equity | ₹24.45 Cr | 1.29% |
| Laxmi Dental Ltd | Equity | ₹20.96 Cr | 1.11% |
| Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹19.84 Cr | 1.05% |
| Ajanta Pharma Ltd | Equity | ₹2.74 Cr | 0.14% |
| Net Current Assets | Cash | ₹-0.3 Cr | 0.02% |
Large Cap Stocks
37.84%
Mid Cap Stocks
22.98%
Small Cap Stocks
34.89%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,832.86 Cr | 96.66% |
| Basic Materials | ₹43.72 Cr | 2.31% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since October 2023

Since October 2023
ISIN INF179KC1HL7 | Expense Ratio 2.08% | Exit Load 1.00% | Fund Size ₹1,896 Cr | Age 2 years | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹8,32,405 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (24-Oct-25)
Returns (Since Inception)
Fund Size
₹1,896 Cr
Expense Ratio
2.08%
ISIN
INF179KC1HL7
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.65%
+3.55% (Cat Avg.)
Since Inception
+30.65%
— (Cat Avg.)
| Equity | ₹1,876.57 Cr | 98.97% |
| Others | ₹19.54 Cr | 1.03% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹198.43 Cr | 10.47% |
| Divi's Laboratories Ltd | Equity | ₹147.07 Cr | 7.76% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹131.38 Cr | 6.93% |
| Lupin Ltd | Equity | ₹129.64 Cr | 6.84% |
| Alkem Laboratories Ltd | Equity | ₹112.58 Cr | 5.94% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹88.28 Cr | 4.66% |
| Ipca Laboratories Ltd | Equity | ₹85.33 Cr | 4.50% |
| Cipla Ltd | Equity | ₹81.83 Cr | 4.32% |
| Torrent Pharmaceuticals Ltd | Equity | ₹72.28 Cr | 3.81% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹68.94 Cr | 3.64% |
| Laurus Labs Ltd | Equity | ₹67.88 Cr | 3.58% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹67.4 Cr | 3.55% |
| Anthem Biosciences Ltd | Equity | ₹61.72 Cr | 3.26% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹60.53 Cr | 3.19% |
| Metropolis Healthcare Ltd | Equity | ₹50.04 Cr | 2.64% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹46.41 Cr | 2.45% |
| Acutaas Chemicals Ltd | Equity | ₹43.72 Cr | 2.31% |
| Gland Pharma Ltd | Equity | ₹40.24 Cr | 2.12% |
| Wockhardt Ltd | Equity | ₹39.16 Cr | 2.07% |
| Cohance Lifesciences Ltd | Equity | ₹37.67 Cr | 1.99% |
| Dr. Lal PathLabs Ltd | Equity | ₹36.79 Cr | 1.94% |
| Fortis Healthcare Ltd | Equity | ₹35.8 Cr | 1.89% |
| Jubilant Pharmova Ltd | Equity | ₹34.28 Cr | 1.81% |
| Piramal Pharma Ltd | Equity | ₹33.88 Cr | 1.79% |
| Sai Life Sciences Ltd | Equity | ₹31.68 Cr | 1.67% |
| Bajaj Healthcare Ltd | Equity | ₹25.48 Cr | 1.34% |
| Pfizer Ltd | Equity | ₹24.45 Cr | 1.29% |
| Laxmi Dental Ltd | Equity | ₹20.96 Cr | 1.11% |
| Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹19.84 Cr | 1.05% |
| Ajanta Pharma Ltd | Equity | ₹2.74 Cr | 0.14% |
| Net Current Assets | Cash | ₹-0.3 Cr | 0.02% |
Large Cap Stocks
37.84%
Mid Cap Stocks
22.98%
Small Cap Stocks
34.89%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,832.86 Cr | 96.66% |
| Basic Materials | ₹43.72 Cr | 2.31% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since October 2023

Since October 2023
ISIN INF179KC1HL7 | Expense Ratio 2.08% | Exit Load 1.00% | Fund Size ₹1,896 Cr | Age 2 years | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹8,32,405 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments